Medicines
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Reporting of side effects
The safety of our patients is very important to us. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
By reporting any side effects that you may experience, you are helping to provide more information on the safety of our medicines. Report a possible side-effect to AstraZeneca by 'report side-effect' below. If you are based in the UK, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Oncology
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Calquence
acalabrutinib
Enhertu
trastuzumab deruxtecan
Faslodex
fulvestrant
Imfinzi
durvalumab
Iressa
gefitinib
Koselugo
selumetinib
Lumoxiti
moxetumomab pasudotox-tdfk
Lynparza
olaparib
Orpathys
savolitinib
Tagrisso
osimertinib
Zoladex
goserelin acetate implant
Cardiovascular, Renal & Metabolism
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Brilinta/Brilique
ticagrelor
Bydureon/Bydureon,BCise
exenatide XR injectable suspension
Byetta
exenatide injection
Crestor
rosuvastatin calcium
Farxiga/Forxiga
dapagliflozin
Komboglyze/Kombiglyze XR
saxagliptin/metformin
Lokelma
sodium zirconium cyclosilicate
Onglyza
saxagliptin
Roxadustat
Qtern
dapagliflozin/saxagliptin
Xigduo/Xigduo XR
dapagliflozin/metformin
Respiratory & Immunology
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Bevespi Aerosphere
glycopyrronium/formoterol
Breztri Aerosphere (PT010)
budesonide/glycopyrrolate/formoterol
Daliresp/Daxas
roflumilast
Duaklir/Brimica
aclidinium/formoterol
Fasenra
benralizumab
Pulmicort
budesonide
Saphnelo
anifrolumab
Symbicort
budesonide/formoterol
Tudorza/Eklira/Bretaris
aclidinium
Rare Disease
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Andexxa/Ondexxya
andexanet alfa
Kanuma
sebelipase alfa
Soliris
eculizumab
Strensiq
asfotase alfa
Ultomiris
ravulizumab
Early access to AstraZeneca investigational medicinal products
We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.
Veeva ID: Z4-42563
Date of preparation: February 2022